NASDAQ:WGS GeneDx (WGS) Stock Price, News & Analysis → RSVP: Charles Payne’s Cash Flow Workshop (From Unstoppable Prosperity) (Ad) Free WGS Stock Alerts $19.52 -0.14 (-0.71%) (As of 05/6/2024 ET) Add Compare Share Share Today's Range$19.29▼$20.6450-Day Range$7.75▼$20.9252-Week Range$1.16▼$21.71Volume615,775 shsAverage Volume359,357 shsMarket Capitalization$509.86 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get GeneDx alerts: Email Address GeneDx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside7.8% Downside$18.00 Price TargetShort InterestBearish6.60% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 22 Articles This WeekInsider TradingAcquiring Shares$349,600 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.02) to ($0.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.18 out of 5 starsMedical Sector741st out of 908 stocksHealth Services Industry8th out of 11 stocks 1.3 Analyst's Opinion Consensus RatingGeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageGeneDx has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.60% of the float of GeneDx has been sold short.Short Interest Ratio / Days to CoverGeneDx has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in GeneDx has recently decreased by 2.73%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldGeneDx does not currently pay a dividend.Dividend GrowthGeneDx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for WGS. Previous Next 3.0 News and Social Media Coverage News SentimentGeneDx has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for GeneDx this week, compared to 1 article on an average week.Search Interest13 people have searched for WGS on MarketBeat in the last 30 days. This is an increase of 30% compared to the previous 30 days.MarketBeat Follows6 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GeneDx insiders have bought 53.08% more of their company's stock than they have sold. Specifically, they have bought $349,600.00 in company stock and sold $228,370.00 in company stock.Percentage Held by Insiders28.10% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for GeneDx are expected to grow in the coming year, from ($2.02) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GeneDx is -3.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GeneDx is -3.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeneDx has a P/B Ratio of 2.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThis is the ONLY AI story you should be worried aboutA.I. is creeping into every aspect of our daily lives… According to billion-dollar fund manager, Louis Navellier, it’s never been more important to A.I.-proof your wealth. He lays out three simple steps to take ASAP in his latest video.Click here to watch it now. About GeneDx Stock (NASDAQ:WGS)GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.Read More WGS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart WGS Stock News HeadlinesMay 1, 2024 | insidertrades.comGeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 1,104 SharesMay 2, 2024 | finance.yahoo.comGeneDx Holdings Corp. (NASDAQ:WGS) Just Reported First-Quarter Earnings And Analysts Are Lifting Their EstimatesMay 6, 2024 | Unstoppable Prosperity (Ad)RSVP: Charles Payne’s Cash Flow WorkshopAre you ready to find untapped value in the stocks you already own… Without selling a single share… Then you need to know these Cash Flow Trade Strategies.May 2, 2024 | americanbankingnews.comGeneDx (NASDAQ:WGS) Hits New 12-Month High on Analyst UpgradeMay 1, 2024 | americanbankingnews.comGeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland Sells 6,325 SharesMay 1, 2024 | americanbankingnews.comGeneDx (NASDAQ:WGS) Price Target Increased to $24.00 by Analysts at TD CowenMay 1, 2024 | americanbankingnews.comGeneDx (NASDAQ:WGS) Price Target Increased to $19.00 by Analysts at BTIG ResearchApril 30, 2024 | finanznachrichten.deGeneDx Holdings Corp.: GeneDx Reports First Quarter 2024 Financial Results and Business HighlightsMay 6, 2024 | Unstoppable Prosperity (Ad)RSVP: Charles Payne’s Cash Flow WorkshopAre you ready to find untapped value in the stocks you already own… Without selling a single share… Then you need to know these Cash Flow Trade Strategies.April 30, 2024 | markets.businessinsider.comGeneDx is about to announce its earnings — here's what to expectApril 30, 2024 | finance.yahoo.comGeneDx Holdings Corp (WGS) (Q1 2024) Earnings Call Transcript Highlights: Soaring Revenues and ...April 29, 2024 | msn.comWGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q1 2024April 29, 2024 | msn.comGeneDx Stock Climbs After Better-Than-Expected Q1 Results, Raises FY24 GuidanceApril 29, 2024 | finance.yahoo.comGeneDx Holdings Corp (WGS) Q1 2024 Earnings: Surpasses Revenue Expectations and Narrows LossesApril 29, 2024 | msn.comGeneDx reports Q1 resultsApril 29, 2024 | globenewswire.comGeneDx Reports First Quarter 2024 Financial Results and Business HighlightsApril 28, 2024 | msn.comGeneDx Q1 2024 Earnings PreviewApril 27, 2024 | finance.yahoo.comGeneDx Holdings Corp. (WGS)April 23, 2024 | finance.yahoo.comGeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease DatasetApril 23, 2024 | globenewswire.comGeneDx Announces Partnership with Komodo Health to Expand Access to World's Largest Rare Disease DatasetApril 4, 2024 | globenewswire.comGeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024March 16, 2024 | finance.yahoo.comWGS Apr 2024 7.500 callMarch 16, 2024 | finance.yahoo.comWGS Apr 2024 7.500 putMarch 14, 2024 | globenewswire.comGeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of GenomicsMarch 13, 2024 | edition.cnn.comGeneDx Holdings Corp. Class AFebruary 26, 2024 | globenewswire.comGeneDx to Participate in 44th Annual Cowen Health Care ConferenceFebruary 25, 2024 | finance.yahoo.comWGS Mar 2024 7.500 putSee More Headlines Receive WGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeneDx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today5/06/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Health services Sub-IndustryN/A Current SymbolNASDAQ:WGS CUSIPN/A CIK1818331 Websema4.com Phone800-298-6470FaxN/AEmployees1,000Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$24.00 Low Stock Price Target$11.00 Potential Upside/Downside-8.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($5.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-175,770,000.00 Net Margins-60.86% Pretax Margin-61.25% Return on Equity-36.23% Return on Assets-20.92% Debt Debt-to-Equity Ratio0.25 Current Ratio3.22 Quick Ratio2.99 Sales & Book Value Annual Sales$202.57 million Price / Sales2.54 Cash FlowN/A Price / Cash FlowN/A Book Value$8.78 per share Price / Book2.24Miscellaneous Outstanding Shares26,120,000Free Float18,782,000Market Cap$513.52 million OptionableOptionable Beta2.17 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Katherine A. Stueland (Age 48)President, CEO & Director Comp: $1.19MMr. Kevin FeeleyChief Financial OfficerMs. Karen PonchnerSenior VP & Head of OperationsMr. Eric Olivares Ph.D.Chief Product & Technology OfficerMr. Devin K. Schaffer J.D.M.B.A., General CounselMr. Paul Kruszka M.D.Chief Medical OfficerMs. Melanie DuquetteChief Growth OfficerSabrina DunbarChief of StaffMore ExecutivesKey CompetitorsInnovAgeNASDAQ:INNVTalkspaceNASDAQ:TALKDocGoNASDAQ:DCGOThe Pennant GroupNASDAQ:PNTGSharecareNASDAQ:SHCRView All CompetitorsInsiders & InstitutionsThompson Davis & CO. Inc.Bought 4,150 shares on 5/2/2024Ownership: 0.092%Katherine StuelandSold 6,325 sharesTotal: $69,828.00 ($11.04/share)Kevin FeeleySold 1,104 sharesTotal: $12,188.16 ($11.04/share)PFG Investments LLCBought 10,424 shares on 4/22/2024Ownership: 0.040%Katherine StuelandSold 8,559 sharesTotal: $90,639.81 ($10.59/share)View All Insider TransactionsView All Institutional Transactions WGS Stock Analysis - Frequently Asked Questions Should I buy or sell GeneDx stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GeneDx in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" WGS shares. View WGS analyst ratings or view top-rated stocks. What is GeneDx's stock price target for 2024? 3 brokers have issued twelve-month target prices for GeneDx's stock. Their WGS share price targets range from $11.00 to $24.00. On average, they anticipate the company's stock price to reach $18.00 in the next year. This suggests that the stock has a possible downside of 7.8%. View analysts price targets for WGS or view top-rated stocks among Wall Street analysts. How have WGS shares performed in 2024? GeneDx's stock was trading at $2.75 on January 1st, 2024. Since then, WGS stock has increased by 609.8% and is now trading at $19.52. View the best growth stocks for 2024 here. When is GeneDx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our WGS earnings forecast. How were GeneDx's earnings last quarter? GeneDx Holdings Corp. (NASDAQ:WGS) released its quarterly earnings results on Tuesday, February, 20th. The company reported ($0.59) EPS for the quarter, beating analysts' consensus estimates of ($0.60) by $0.01. The business earned $57.42 million during the quarter, compared to analysts' expectations of $57 million. GeneDx had a negative net margin of 60.86% and a negative trailing twelve-month return on equity of 36.23%. When did GeneDx's stock split? GeneDx shares reverse split on the morning of Thursday, May 4th 2023. The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What guidance has GeneDx issued on next quarter's earnings? GeneDx updated its FY 2024 earnings guidance on Monday, April, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $235.0 million-$245.0 million, compared to the consensus revenue estimate of $226.1 million. Who are GeneDx's major shareholders? GeneDx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Thompson Davis & CO. Inc. (0.09%) and PFG Investments LLC (0.04%). Insiders that own company stock include Anthony Prentice, Casdin Capital, Llc, Daniel Emmett Clark, Eric Schadt, Isaac Ro, James Coffin, Jason Ryan, Kareem Saad, Karen Ann White, Katherine Stueland, Keith A Meister, Kevin Feeley, Richard C Pfenniger Jr, Richard Miao, Shawn Assad and Tactical Opportunit Blackstone. View institutional ownership trends. How do I buy shares of GeneDx? Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:WGS) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldCould Your Accounts Be Frozen?Allegiance GoldAI “wealth window” is closing June 25thParadigm PressThe asset beating inflation by 4xColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsElon to Transform U.S. Economy? Porter & CompanyIncredible Opportunity to Retire FAST!Crypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
